THE CONTINUUM OF CARE IN mCRC: OPTIMIZING USE OF EGFR ANTIBODIES

Introduction

Introduction (cont)

Liquid Biopsy

Tissue-Based vs Liquid Biopsy RAS Analysis: Pros and Cons

Testing for Circulating Tumor DNA

Role of RAS Testing in the Treatment of mCRC

Case Introduction

Molecular Features to Be Considered When Selecting First-Line Therapy

Treatment of CRC Metastatic Disease: ESMO 2016, Biomarkers Recommended for Routine Assessment

Tissue-Based vs Plasma Biomarker Testing

Case Discussion: Assessment of Biomarkers Before First-Line Treatment Selection

Case Discussion: First-Line Treatment

Molecular Considerations at Progression to First-Line Anti-EGFR Therapy

Case Discussion: Second-Line Treatment

Molecular Considerations at Progression to Second-Line Therapy

Retest for RAS?

Anti-EGFR Rechallenge Strategy

How Can Liquid Biopsy-Based Biomarker Testing Potentially Guide Treatment Decisions After Anti-EGFR Therapy? Ongoing Trials

HERACLES Trial

Rechallenge With Anti-EGFR Therapy: FIRE-4 Study

Case Discussion: Third-Line Treatment

Concluding Remarks

Abbreviations

Abbreviations (cont)

Abbreviations (cont)